Retatrutide met primary and key secondary endpoints in a 2339-participant, randomized, double-blind, placebo-controlled phase 3 trial, demonstrating clinically meaningful weight reduction across 4, 9, ...

High-grade neuroendocrine neoplasms (NENs) are rare and aggressive tumors with a very poor prognosis. Over 90% originate in the lung and only 3% are of gastroenteropancreatic (GEP) origin 1,2. The ...

iPercent body weight reduction with retatrutide 4 mg was a key secondary endpoint. iiThe extension period enrolled 532 participants with BMI ≥35 at baseline who had completed the main 80-week study ...